Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

year 2012.  Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21648922.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering conference ID# 21648922.  The webcast will remain available on the company's website until the next earnings call.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment a
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield ... skin while battling the weakening threat of inflammaging, ... is formulated with star ingredient GLYCOSEA, a complex ... a complex of soothing minerals and trace elements. ...
(Date:4/30/2015)... Clinovo Staffing Solutions will ... held in Orlando, FL on May 17-20th, 2015. ... Leslie Kolman, Manager of Staffing Solutions, will present Clinovo’s ... Booth #17. , “We are excited to be ... Says Trisha Heredia, Senior Director of Staffing Solutions at ...
(Date:4/29/2015)... According to a new market research report ... Non-Portable), Component (Accelerometer, Proximity Probe, & Others), Application ... & Others), & Geography - Global Forecast to ... $1,453.76 Million by 2020, at a CAGR of ... 92 figures spread through 205 pages and in-depth ...
Breaking Biology Technology:WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... 2010 GeNO LLC ( www.genollc.com ), a privately ... the Phase 2 clinical trial for its stand-alone gas ... be studied for nitric oxide delivered via the GeNO ... for administration as an adjunct to right heart catheterization ...
... 2010 / PRNewswire/ -- AltheaDx, Inc. – ... of a strategic partnership with Compendia Bioscience to ... validation and bioinformatics. The two companies will jointly ... biomarker discovery and subsequent development of tests that ...
... Dec. 8, 2010 Shrink Nanotechnologies, Inc. ("Shrink") ... innovative nanotechnology company developing products and licensing opportunities ... sensors and biotechnology research and development tools businesses, ... multi-year development and manufacturing agreement with EV Group, ...
Cached Biology Technology:GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System 2GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System 3AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™ 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 3Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 4Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 5
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... This release is available in Spanish . ... consequences of climate change, and affects crops in particular. However, Anabel ... has confirmed that in the case of barley at least, climate ... lack of water. Climate change is in fact also responsible for ...
... 25, 2012) The evolutionary processes of unicellular ... John Torday, Ph.D., a lead investigator at Los ... co-authored a book entitled Evolutionary Biology, Cell-Cell Communication ... evolutionary biology. Rather than focusing on multicellular ...
... Philadelphia, PA, January 25, 2012 A significant obstacle ... in obtaining living brain tissue for study so that ... basic cellular neuroscience now suggest that, for some purposes, ... to research psychiatric disease mechanisms. But where can one ...
Cached Biology News:Barley adapts to climate change 2Barley adapts to climate change 3LA BioMed's Dr. John Torday examines evolution from a cellular perspective 2In schizophrenia research, a path to the brain through the nose 2
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Biology Products: